PHARMACIE SALAVERT - LANDJAS is a French company
founded 20 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in DONZY (58220),
this company of category PME
shows in 2023 a revenue of 2.8 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE SALAVERT - LANDJAS (SIREN 482279080)
Indicator
2025
2024
2023
2022
2021
2020
2019
2017
Revenue
N/C
N/C
2 800 715 €
N/C
N/C
N/C
2 060 283 €
2 108 236 €
Net income
282 723 €
247 399 €
309 094 €
277 040 €
173 849 €
41 694 €
33 170 €
71 946 €
EBITDA
N/C
N/C
314 563 €
N/C
N/C
N/C
139 228 €
252 831 €
Net margin
N/C
N/C
11.0%
N/C
N/C
N/C
1.6%
3.4%
Revenue and income statement
In 2025, PHARMACIE SALAVERT - LANDJAS generates positive net income of 283 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 72 k€ -> 283 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
282 723 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 92%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.335%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
92.26%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2019
2020
2021
2022
2023
2024
2025
Debt ratio
26.538
5.067
0.534
0.362
0.25
0.338
0.343
0.335
Financial autonomy
72.283
85.164
90.842
89.886
91.036
92.444
90.102
92.26
Repayment capacity
6.396
0.585
None
None
None
0.023
None
None
Cash flow / Revenue
3.413%
7.506%
None%
None%
None%
11.235%
None%
None%
Sector positioning
Debt ratio
0.342025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Excellent
In 2025, the debt ratio of PHARMACIE SALAVERT - LANDJAS (0.34) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
92.26%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Excellent+16 pts over 3 years
In 2025, the financial autonomy of PHARMACIE SALAVERT - LANDJAS (92.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.02 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Excellent
In 2023, the repayment capacity of PHARMACIE SALAVERT - LANDJAS (0.02) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 618.73. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
369.872
310.47
410.262
404.578
514.171
616.82
473.51
618.733
Interest coverage
6.795
4.355
None
None
None
1.859
None
None
Sector positioning
Liquidity ratio
618.732025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Excellent
In 2025, the liquidity ratio of PHARMACIE SALAVERT - LANDJAS (618.73) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
1.86x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE SALAVERT - LANDJAS (1.9x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE SALAVERT - LANDJAS
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2019
2020
2021
2022
2023
2024
2025
Operating WCR
504 775 €
542 761 €
0 €
0 €
0 €
401 735 €
0 €
0 €
Inventory turnover (days)
22
29
0
0
0
24
0
0
Customer payment term (days)
6
5
0
0
0
5
0
0
Supplier payment term (days)
32
36
0
0
0
20
0
0
Positioning of PHARMACIE SALAVERT - LANDJAS in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE SALAVERT - LANDJAS is estimated at
4 491 088 €
(range 3 047 673€ - 7 047 136€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
3047k€4491k€7047k€
4 491 088 €Range: 3 047 673€ - 7 047 136€
NAF 5 année 2025
Valuation method used
Net Income Multiple
282 723 €
×
15.9x
=4 491 088 €
Range: 3 047 674€ - 7 047 136€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE SALAVERT - LANDJAS with other companies in the same sector:
Frequently asked questions about PHARMACIE SALAVERT - LANDJAS
What is the revenue of PHARMACIE SALAVERT - LANDJAS ?
The revenue of PHARMACIE SALAVERT - LANDJAS in 2023 is 2.8 M€.
Is PHARMACIE SALAVERT - LANDJAS profitable?
Yes, PHARMACIE SALAVERT - LANDJAS generated a net profit of 283 k€ in 2025.
Where is the headquarters of PHARMACIE SALAVERT - LANDJAS ?
The headquarters of PHARMACIE SALAVERT - LANDJAS is located in DONZY (58220), in the department Nievre.
Where to find the tax return of PHARMACIE SALAVERT - LANDJAS ?
The tax return of PHARMACIE SALAVERT - LANDJAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE SALAVERT - LANDJAS operate?
PHARMACIE SALAVERT - LANDJAS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart